by The global surgical sphincteroplasty market size was valued at USD 2.3 billion in 2020, and is predicted to be worth around USD 5.67 billion by 2030, registering a CAGR of 6.8% during the forecast period 2022 to 2030.
Buy this Research Report study@ https://www.visionresearchreports.com/report/sample/39094
Table of Contents
Surgical Sphincteroplasty Market Growth Factors
The growing prevalence of Anal Incontinence (AI), cost-effectiveness of sphincteroplasty, and rising incidence of obstetric injury post-childbirth are the key factors driving the market. Anal Incontinence (AI) is a chronic condition that affects one out of every three individuals, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Additionally, studies suggest that AI affects nearly 15% of women living in the community and half of the women in nursing homes. Factors such as age, obstetric trauma, pelvic surgery, chronic diarrhea, obesity, and other medical conditions, such as diabetes and stroke, increase the risk of Al.
The growing prevalence of anal incontinency (AI), increasing frequency of obstetric injury after childbirth, rise in innovative techniques to treat AI, and growing clinical studies are the key contributing factors propelling the growth of the market. Presence of fewer market players makes this a less competitive market. However, to strengthen their market position they are constantly involved in adopting developmental strategies like collaboration and acquisition with other market players.
Surgical Sphincteroplasty Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 5.67 billion by 2030 |
| Growth Rate | CAGR of 6.8% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Medtronic; Pelvalon; Hill-Rom Services, Inc; McKesson; B. Braun; Becton, Dickinson and Company; Novo Surgical, Inc.; Surgical Holdings; Salix Pharmaceutical Inc.; Johnson & Johnson |
By Type Analysis
The surgical (sphincteroplasty) segment accounted for the largest revenue share of 28.1% in 2020. Sphincteroplasty is the most popular surgical treatment for anal incontinence.
Direct apposition is performed by cutting the ends of the internal and external anal sphincter (IAS & EAS) and suturing them in layers to treat AI. It held a share of 8.3% in the surgical segment.
The non-surgical segment is estimated to witness the highest CAGR of 6.9% during the forecast period, owing to its growing adoption among the geriatric population and the ability to quickly regain anal sphincter control upon administration.
It is further divided into sacral nerve stimulation, vaginal balloon inserts, and other treatment such as artificial bowel sphincter and solesta. Patients with end-stage AI and those failing to respond to the conventional treatment, have witnessed promising results of the non-surgical techniques
By Regional Analysis
North America dominated the market for surgical sphincteroplasty and accounted for the largest revenue share of 34.9% in 2020. Due to the improved healthcare infrastructure, and presence of leading market players in this region, the region is expected to capture the largest market share.
The Asia Pacific region witnessed the highest CAGR of 7.1% during the forecast period. Factors such as the rise in the aging population increased adoption of cost-effective surgeries like sphincteroplasty, and improved government expenditure on the healthcare sector is said to drive the market in the region.
Read also @ Biopharmaceutical CMO and CRO Market Size Hit US$ 60.1 billion by 2030
Major Key Players Covered in The Surgical Sphincteroplasty Market Report include
- Medtronic
- Hill-Rom Services, Inc.
- McKesson
- B. Braun
- Becton, Dickinson and Company
- Novo Surgical, Inc.
- Surgical Holdings
- Pelvalon
- Salix Pharmaceutical Inc.
- Johnson & Johnson
Surgical Sphincteroplasty Market Segmentation
- By Type
- Surgical (sphincteroplasty)
- Direct apposition sphincteroplasty
- Overlapping sphincteroplasty
- Non-Surgical
- Sacral nerve stimulation
- Vaginal balloon inserts
- Others
- Surgical (sphincteroplasty)
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Surgical Sphincteroplasty Market, By Type
7.1. Surgical Sphincteroplasty Market, by Type, 2021-2030
7.1.1. Surgical (sphincteroplasty)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Non-Surgical
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Surgical Sphincteroplasty Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, by Type (2017-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, by Type (2017-2030)
Chapter 9. Company Profiles
9.1. Medtronic
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Hill-Rom Services, Inc.
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. McKesson
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. B. Braun
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Becton, Dickinson and Company
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Novo Surgical, Inc.
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Surgical Holdings
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Pelvalon
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39094
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
